← SynDRA
GSK-2256098
SynDRA canonical compound SYN0040210 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | PTK2 |
|---|
| Mechanism of action | kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- PTK2 INHIBITOR
- Focal adhesion kinase 1 inhibitor
- kinase inhibitor
Cross-references
Synonyms
- Gsk2256098
- Focal adhesion kinase inhibitor (oral, cancer), GlaxoSmithKline
- GSK2256098
- R7O0O4110G
- RefChem:144510
- FAK Inhibitor GSK2256098
- Focal Adhesion Kinase Inhibitor GSK2256098
- GTPL7939
- MFCD30502650
- BVAHPPKGOOJSPU-UHFFFAOYSA-N
- C20H23ClN6O2
- SCHEMBL691518
- UNII-R7O0O4110G
- orb1305806
- SCHEMBL29361345
- EX-A671
- BDBM50568532
- EBC-73187
- NSC800999
- s8523
- GSK2256098 [WHO-DD]
- AKOS030627136
- CCG-268826
- CS-6083
- NSC-800999
- GSK2256098?
- NCGC00482799-02
- AC-29885
- AS-74894
- SY235581
- DB-192255
- HY-100498
- F865625
- G733402
- 4CSJ8BJ597
- CS-1231942
- GSK-2256098 (hydrochloride)
- UNII-4CSJ8BJ597
Look up GSK-2256098 in the interactive SynDRA portal →